Recommendations from the WHO guideline for the prevention, diagnosis, and treatment of infertility†.

Infertility is a disease of the male and female reproductive systems, defined as the failure to achieve a pregnancy after 12 months of regular unprotected sexual intercourse ( Zegers-Hochschild et al. , 2009 ; World Health Organization, 2018 ). Globally, approximately one in six people of reproductive age experience infertility at some stage in their lives ( World Health Organization, 2023 ). Lifetime prevalence of infertility is 17.5%, while period prevalence is 12.6%. In addition, infertility prevalence does not differ significantly between high-income (17.8%) and low- and middle-income countries (LMICs) (16.5%), or according to world regions, indicating that infertility is a global public health issue affecting people from all regions and countries ( World Health Organization, 2023 ). A large World Health Organization (WHO) multi-country study involving 8500 couples in 25 countries found that infertility was due to female factors alone in 30.6%, both male and female factors in 26.3%, and male factors alone in 18.7% of cases ( Cates et al. , 1985 ; World Health Organization, 1992 ). No cause was found in 10.8% of cases ( Cates et al. , 1985 ; World Health Organization, 1992 ). The remaining 13.3% got pregant during study investigations. Based on this WHO study, male factors contributed wholly or in part to 45.1% of infertility cases. The most common identifiable causes of female infertility included anovulatory and oligo-ovulatory disorders (26.1%), endometriosis (4.8%), pelvic (including uterine) adhesions (14.8%), bilateral tubal blockage (17.7%), acquired tubal abnormalities (11.6%), and hyperprolactinemia (6.7%); rates of infertility due to tubal causes were higher in LMICs compared to high-income countries ( Cates et al. , 1985 ; World Health Organization, 1987 ; World Health Organization, 1992 ). Among males, identifiable causes of infertility included varicocele (13.1%), primary testicular failure (12%), and accessory gland infection (7.1%). Abnormal semen parameters (morphology and motility) were identified in 9.7% of males diagnosed with infertility ( World Health Organization, 1992 ). However, these multi-country data are relatively old and new patterns may have emerged across high-income, middle-income, and low-income settings. Individuals and couples have the right to decide the number, timing, and spacing of their children ( United Nations, 1979 ); however, there is a gap between desired and actual fertility for many people in many settings ( Beaujouan and Berghammer, 2019 ). Addressing infertility is an important part of enabling individuals and couples to achieve their fertility preferences. WHO recognizes that the provision of high-quality services for family-planning, including fertility care services, is one of the core elements of reproductive health. The WHO guideline on infertility aims to provide recommendations related to prevention, as well as diagnosis and treatment of female-factor (tubal, ovulatory dysfunction, and uterine causes), male-factor, and unexplained-factor infertility ( World Health Organization, 2025 ). Because the recommendations in the guideline are based on current best evidence and the values and preferences of individuals and couples, it may help people to receive high-quality care and achieve their fertility preferences. This article presents a summary of the guideline recommendations.

The GDG made a total of 40 recommendations and good practice statements, which are related to different aspects of infertility. Good practice statements (n = 6) provide guidance on the general management of infertility including: (i) selection of tests, (ii) listening to individuals and couples with infertility, (iii) choosing treatment decisions, (iv) clinical follow-up, and (v) documenting outcomes of treatment as shown in Table 2 . General approach to management of infertility. select diagnostic tests based on the clinical findings from medical history and physical examination to ensure that evaluation is systematic and cost-effective; listen to individuals and couples, respect their preferences, discuss if psychological and social or peer support is needed, and if needed, provide it or refer patients for it; base treatment decisions on benefits and harms, patient values and preferences, feasibility, costs and availability of resources; consider the cost-effectiveness of treatment (e.g. least expensive, but effective treatments should be provided initially); discuss the plan for clinical follow-up and management of potential risks that may occur during infertility treatment; document the outcomes of pregnancies resulting from infertility treatment. In relation to prevention, the guideline provides recommendations related to the provision of information about fertility and infertility (n = 1) as well as reduction of infertility risk from sexually transmitted infections (STIs; n = 1), lifestyle factors (n = 1), and tobacco use (n = 1) as shown in Table 3 . Prevention of infertility. Low-cost strategies may include information in digital or paper format when opportunities occur in schools, at primary health care centres or at reproductive health (contraceptive, sexual health) clinics. Information adapted to local contexts and audiences, including how to reduce risk factors for infertility, lifestyle modification, age-related fertility decline/potential, and timely medical consultation, may increase the likelihood of information uptake and beneficial outcomes. Lifestyle advice may include advice to change diet, alcohol intake, smoking, physical activity and/or weight management. This is an existing WHO recommendation for the general population that also applies to individuals and couples who are planning a pregnancy, attempting to achieve a pregnancy or with infertility, given the association between infertility and current or previous history of smoking. Assessment of lifestyle, including the use of tobacco, is part of medical history when evaluating individuals and couples for infertility. Brief advice is advice to stop using tobacco—usually taking only a few minutes—given to all tobacco users, usually during a routine consultation or interaction. Brief advice should include informing individuals and couples that (i) use of tobacco, particularly smoking, is associated with a higher risk of infertility; (ii) the risk of infertility due to tobacco smoking is higher among women; and (iii) a range of interventions to assist in cessation of tobacco use exist. Brief advice should include the 5 As: asking about tobacco use; advising to make a quit attempt; assessing readiness to quit; assisting in making a quit plan; and arranging a follow-up. Advice should be tailored or personalized based on individual circumstances. All adults interested in quitting smoking should be offered or referred to interventions to assist in tobacco cessation as recommended by existing WHO guidelines for preventing tobacco use uptake, promoting tobacco cessation or diagnosing and treating tobacco dependence. If symptoms of an STI are present, or if infection is confirmed, WHO guideline recommendations on the management of STIs are available. WHO, World Health Organization. In terms of diagnosis, recommendations for diagnosing infertility caused by ovulatory dysfunction (n = 3), tubal disease (n = 1), or uterine cavity abnormalities (n = 5) among females are provided. For males, the guideline provides recommendations regarding when a semen test should be repeated (n = 2). Also included is a recommendation for diagnosing unexplained infertility (n = 1) ( Table 4 ). An algorithm that elaborates recommendations related to diagnosis of female-factor and unexplained-factor infertility is shown in Fig. 1 . Algorithms were developed to illustrate the recommendations related to the assessment of the uterine cavity ( Fig. 2 ) as well as male-factor infertility ( Fig. 3 ) which are represented in Table 4 . Diagnostic algorithm for female-factor and unexplained-factor infertility . a Infertility is defined as failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. b See Section 5.7 in the full guideline ( World Health Organization, 2025 ). c See detailed diagnostic algorithm for uterine factors in Fig. 2 in this manuscript and Figure 5.2. in the full guideline ( World Health Organization, 2025 ) d Based on clinical findings; see Good Practice Statements in Chapter 3 in the full guideline ( World Health Organization, 2025 ). e Repeat if initial test result shows anovulation. f Follow the pathway for investigating the cause of anovulation or oligo-ovulation shown on the right side of this chart. g Such as adenomyosis or endometriosis. h See recommendation on semen analysis in Section 5.7 in the full guideline ( World Health Organization, 2025 ). i Such as polycystic ovarian syndrome (PCOS), functional hypothalamic amenorrhoea, premature ovarian insufficiency (POI), hypothyroidism, hyperthyroidism, hyperprolactinaemia, among others. See Sections 5.1–5.4 in the full guideline ( World Health Organization, 2025 ) j For example, due to advanced age, ovarian surgery, POI. k See Chapters 6–10 in the full guideline for treatment recommendations ( World Health Organization, 2025 ). 2D US, 2-dimensional ultrasound; 3D US, 3-dimensional ultrasound; AFC, antral follicle count; AMH, anti-Müllerian hormone; E2, estradiol; HPO, hypothalamic–pituitary–ovarian; HSG, hysterosalpingogram; HyCoSy, hysterosalpingo contrast sonography; PRL, prolactin; SIS, saline infusion sonohysterography; STI, sexually transmitted infection; T, testosterone; TSH, thyroid-stimulating hormone; WHO, World Health Organization. Diagnostic algorithm for the assessment of the uterine cavity . a See Fig. 1 of this manuscript and Figure 5.1 in the full guideline ( World Health Organization, 2025 ) for the overall diagnostic algorithm of female-factor infertility. b See recommendations for the treatment of uterine-factor infertility in Table 2 of this article and Chapter 8 in the full guideline ( World Health Organization, 2025 ). c See Table 5.7 in the full guideline ( World Health Organization, 2025 ) for the comparison of 3D US, SIS, 2D US, and HSG with hysteroscopy for the diagnosis of uterine cavity disorders. 2D US, 2-dimensional ultrasound; 3D US, 3-dimensional ultrasound; HSG, hysterosalpingogram; SIS, saline infusion sonohysterography. Diagnostic algorithm for male-factor infertility . a See the WHO laboratory manual for the examination and processing of human semen (sixth ( WHO, 2021b ) or latest edition). b Consider post-ejaculate urinalysis to rule out retrograde ejaculation if low (or no) semen ejaculate volume; see WHO laboratory manual for the examination and processing of human semen (sixth ( WHO, 2021b ) or latest edition). c See Chapter 4 in the full guideline ( World Health Organization, 2025 ), for details on information provision. d Evaluation should include PE and SA regardless of history findings. e See Chapter 4 in the full guideline ( World Health Organization, 2025 ) and the WHO guideline for the management of sexually transmitted infections ( World Health Organization, 2021b ). f Female evaluation is essential and should proceed regardless of semen analysis outcome; see Fig. 1 in this article and Chapter 5 in the full guideline ( World Health Organization, 2025 ) for the evaluation of the female. g Healthcare provider with appropriate qualifications; for example, urologist, clinical andrologist, or reproductive medicine specialist with relevant qualifications. h See Chapters 6, 7, and 8 in the full guideline ( World Health Organization, 2025 ). i See Section 5.8 and Chapter 10 in the full guideline ( World Health Organization, 2025 ). N/A, not applicable; PE, physical examination; SA, semen analysis; WHO, World Health Organization. Diagnosis of female-, male-, and unexplained-factor infertility (see Figs 1 , 2 , and 3 ). Mid-luteal serum progesterone levels are assessed ∼7 days before the expected onset of the next menses, noting that the specific cycle day can vary based on the length of the menstrual cycle. A repeat mid-luteal serum progesterone measurement could be performed in a subsequent menstrual cycle, considering the turnaround time for tests and cycle-to-cycle variations. Age is the most important predictor of ovarian reserve. Therefore, ordering an ovarian reserve test in addition to age assessment may not substantially improve the accuracy of diagnosing low ovarian reserve (as assessed by poor response to stimulation). Note that the ability of age to predict ovarian reserve may be limited in some clinical scenarios, such as cases of premature ovarian insufficiency. Selection of the test to assess ovarian reserve should be based on relative acceptability, availability, and resources in local contexts. When selecting whether to use HSG or HyCoSy to assess tubal patency, consider feasibility, the availability of trained health care providers and the potential for allergy. In settings where 3D US is already available within the existing resources, 3D US may be the preferred option. Health care providers may choose to use 2D US rather than HSG when resources are limited. Follow-up would be required for women who are negative on 2D US but still suspected of uterine cavity disorder because of high rates of false negatives. The latest edition of the WHO laboratory manual for the examination and processing of human semen provides WHO reference ranges for semen parameters and details about the standardized procedures for semen collection and analysis. failure to achieve a pregnancy after 12 months of regular unprotected sexual intercourse; normal physical examination and medical history in both the male and female; presumptive confirmation of ovulation and patent tubes in the female partner; and semen parameters that are within the WHO reference ranges in the male partner. WHO, World Health Organization. Regarding treatment, the guideline provides recommendations related to the treatment of female-factor infertility, caused by polycystic ovary syndrome (PCOS, n = 6), tubal disease (n = 5), uterine septae (n = 1). Recommendations related to the treatment of female-factor infertility are shown in the following Table 5 . Given its complexity, a treatment algorithm was developed to illustrate recommendations for anovulatory infertility due to PCOS ( Fig. 4 ). Treatment algorithm for anovulatory infertility due to PCOS . a Baseline investigations: 1. Diagnosis of PCOS according to the Rotterdam criteria (endocrine profile and pelvic ultrasound scan). See Chapter 6.1 in the full guideline ( World Health Organization, 2025 ). 2. Additional assessment tests may be required, including during the pre-pregnancy period. See Chapter 3 in the full guideline ( World Health Organization, 2025 ). 3. Consider assessing tubal patency. See Chapter 5.5 in the full guideline ( World Health Organization, 2025 ). 4. Assess the male partner, including semen analysis. See Chapter 5.7 in the full guideline ( World Health Organization, 2025 ). b Such as a healthy diet, regular physical activity and/or weight management. c Use repeated cycles based on shared decision-making considering age and resources. d Monitor patients regularly (with ultrasound as needed) and manage potential risks that may occur during treatment. See Chapter 3 and Chapter 6.1 in the full guideline ( World Health Organization, 2025 ). e If capacity for side-effect management exists. f Use IVF as third-line medical treatment unless other factors (e.g. male factors or tubal factor infertility) exist and manage potential risks (such as OHSS) that may occur during treatment. See Chapter 3 and Chapter 6.1 in the full guideline ( World Health Organization, 2025 ). LOD, laparoscopic ovarian drilling; OHSS, ovarian hyperstimulation syndrome; PCOS, polycystic ovary syndrome. This algorithm was adapted from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome ( Teede et al. , 2023 ). Treatment of female-factor infertility (see Fig. 4 ). For females with infertility due to ovulatory dysfunction caused by polycystic ovary syndrome (PCOS), WHO suggests using letrozole over clomiphene citrate or metformin. Using letrozole alone rather than with metformin is suggested. Where off-label use of letrozole is not permitted, use of clomiphene citrate with metformin rather than clomiphene citrate alone or metformin alone is suggested. Conditional recommendation, low certainty of evidence for letrozole compared to clomiphene citrate, low certainty evidence for letrozole compared with metformin alone, and very low certainty of evidence for letrozole compared to letrozole with metformin Conditional recommendation, moderate certainty of evidence for clomiphene citrate compared to clomiphene with metformin, very low certainty of evidence for clomiphene citrate compared to metformin After surgery, a reasonable minimum time to wait to achieve pregnancy before pursuing other interventions, such as IVF, is 1 year. This recommendation does not apply to females who have had previous tubal sterilization. This recommendation does not apply to females who have had previous tubal sterilization. When selecting whether to use salpingectomy or tubal occlusion, consider feasibility, availability of trained health care providers and presence of adhesions. In settings where salpingectomy and tubal occlusion are not available or feasible, transvaginal aspiration may be offered. WHO, World Health Organization. Recommendations related to the treatment of male-factor infertility are shown in the following Table 6 . Most of these relate to the management of varicocele (n = 4). Based on available evidence, the GDG did not make a recommendation for or against the use of antioxidant supplements in males. Treatment of male-factor infertility. Optimal nutrition is important during the pre-pregnancy period for the couple; however, the effects of antioxidant supplements for males with specific male-factor pathologies in couples with infertility are currently not known. Males with clinical varicocele and semen parameters that are outside the WHO reference ranges are more likely to benefit from receiving treatment for varicocele, compared to men with semen parameters within the WHO reference ranges. This recommendation applies to males with varicoceles in couples with infertility who are not undergoing treatment with ART. When selecting whether to use surgical or radiological treatment, consider feasibility, the availability of trained health care providers and patient preferences regarding the type of treatment procedure. This recommendation applies to males with varicoceles in couples with infertility who are not undergoing treatment with ART. Subinguinal microsurgery is a common surgical varicocelectomy procedure, while other surgical procedures include non-microscopic open approaches (such as inguinal and retroperitoneal) and laparoscopic methods. In settings where the expertise to perform microscopic surgery is not available, other surgical techniques may be used. This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with ART. When selecting whether to use an inguinal or retroperitoneal surgical procedure, consider feasibility and the availability of trained health care providers. This recommendation applies to males with varicocele in couples with infertility who are not undergoing treatment with ART. WHO, World Health Organization. Recommendations (n = 6) and associated treatment algorithm related to the treatment of unexplained infertility is shown in the following Table 7 and Fig. 5 , respectively. Treatment algorithm for unexplained infertility . a Infertility is defined as failure to achieve a pregnancy after 12 months or more of regular unprotected sexual intercourse. b Criteria for the diagnosis of unexplained infertility: • failure to achieve a pregnancy after 12 months of regular unprotected sexual intercourse; • normal physical examination and medical history in both the male and female; • presumptive confirmation of ovulation and patent tubes in the female partner; and • semen parameters that are within the WHO reference ranges in the male partner. See Chapter 5.8 in the full guideline ( World Health Organisation, 2025 ). c Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. d The duration of expectant management was typically 3–6 months in studies informing this recommendation. e The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. f If off-label use of letrozole is allowed. g If capacity for side-effect management exists. h Individualized approach or under research conditions. S-IUI, stimulated intrauterine insemination; IVF, in vito fertilization; ICSI, intracytoplasmic sperm injection. Treatment of unexplained infertility (see Fig. 5 ). Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. The duration of expectant management was typically 3–6 months in studies informing this recommendation. Expectant management refers to monitoring the couple with the expectation that pregnancy will be achieved without medical intervention. It includes providing advice on lifestyle and the most fertile days of the menstrual cycle, and monitoring if pregnancy will occur; however, no medical intervention is provided. The duration of expectant management was typically 3–6 months in studies informing this recommendation. When selecting whether to use clomiphene citrate or letrozole, consider the applicable national laws and regulations related to off-label use of letrozole. The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. The optimal number of S-IUI cycles is unknown; in the studies used to inform this recommendation, different numbers of cycles were provided, ranging from one to six, with more recent studies providing three to six cycles. WHO, World Health Organization.

The guideline was developed in accordance with the 2014 WHO handbook for guideline development ( World Health Organization, 2014 ). In 2018, a WHO steering group was convened to facilitate the scoping of the recommendation questions. A Guideline Development Group (GDG) was established, which included 30 members from different regions and with expertise in different topics related to the prevention, diagnosis, and treatment of infertility, and consisted of clinicians, researchers, implementers, and patient groups. GDG members completed and regularly updated a WHO declaration of interests (DOI) form. All declared interests are shown in Supplementary Tables S1 and S2 . The votes of four GDG members were not counted on specific recommendations in which a conflict of interest existed. The GDG met virtually on many occasions to brainstorm and prioritize questions. Outcomes identified as critical and important for decision-making included live birth rates, ongoing pregnancy rates, clinical pregnancy rates, quality of life, multiple pregnancy, miscarriage, and preterm birth. To inform the recommendations, systematic reviews of randomized and non-randomized studies were conducted de novo or existing reviews were updated. Searches spanned 1990 to December 2019 in MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and LILACS. Additional searches up to 2023 were conducted for selected questions. Cochrane methods for systematic reviews ( Higgins et al. , 2019 ) were followed, and subgroup analyses conducted when data were available for key covariates such as body mass index (BMI) or semen parameters. A search was conducted in the Retraction Watch Database ( The Center for Scientific Integrity, 2025 ) for retracted studies included in the systematic reviews. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach ( Schünemann et al. , 2013 ), based on considerations of risk of bias, inconsistency, indirectness, imprecision, publication bias, effect size, dose–response, and opposing confounding. Certainty of evidence was graded as high, moderate, low, or very low. Evidence about benefits and harms was summarized in the GRADE summary of findings tables and Evidence Profiles. Evidence to decision framework tables (EtDs) were produced for each recommendation and presented to the GDG using GRADEpro online software ( www.gradepro.org/ ). The GDG met virtually to review and interpret the evidence, and to make judgments about the balance of desirable and undesirable consequences of the options. Consequences included the balance of benefits, harms, patients’ values, certainty of evidence, costs and resources, feasibility, acceptability, and equity. Using the GRADE approach, the strength of each recommendation was rated as either strong or conditional. Strong recommendations are presented using the wording ‘ WHO recommends … ’, while conditional recommendations are worded as ‘ WHO suggests … ’. Strong and conditional recommendations have different implications ( Table 1 ). Based on GRADE guidance ( Guyatt et al. , 2016 ), good practice statements were made in topics where the GDG agreed that the guidance was necessary, but a review of the evidence was not warranted because the benefits of the practice were unequivocal and other factors (such as equity) would not have an impact. Implications of the strengths of GRADE recommendations. Most individuals in this situation would want the recommended course of action and only a small proportion would not. Formal decision aids are not likely to be needed to help individuals make decisions consistent with their values and preferences. Most individuals should receive the recommended course of action. Adherence to this recommendation according to the guideline could be used as a quality criterion or performance indicator. Clinicians should recognize that different choices will be appropriate for each individual and that clinicians must help each individual arrive at a management decision consistent with the individual’s values and preferences. Decision aids may be useful to help individuals make decisions consistent with their values and preferences. GRADE, Grading of Recommendations, Assessment, Development and Evaluation; WHO, World Health Organization. All decisions on recommendations were reached by discussion and consensus in virtual meetings, informed by GDG votes in GRADEPro online software indicating agreement or disagreement with recommendation statements drafted by topic leaders, the strength of the recommendations, judgments in all EtD domains, and any remarks. Recommendations with <80% agreement underwent discussion and revisions, whereas recommendations with ≥80% agreement were presented to the GDG for confirmation and a plan for addressing minor comments to improve the clarity of recommendation and accompanying EtDs. Implementation considerations were written according to discussions and comments made by the GDG. Algorithms were developed to illustrate the recommendations. The full guideline document was circulated to the GDG, reviewed and approved. An External Review Group (ERG) that included 30 clinical experts, policymakers, and patient advocates reviewed the recommendations and provided feedback on critical implementation considerations. The guideline was approved by WHO.

This is a summary of the first WHO guideline for the prevention, diagnosis, and treatment of infertility ( World Health Organization, 2025 ), which aims to improve the implementation of evidence-based interventions related to infertility. Although the guideline is primarily intended for use by health care professionals involved in the provision of fertility care (including physicians, embryologists, nurses, midwives, laboratory specialists, and other health care providers), it will be an important source for other interest holders. Policymakers responsible for the development of national health (and other) policies, services, and financing can use these recommendations to inform national guidelines. In addition, the guideline can be used to inform the work of professional patient support organization, as well as advocacy groups, funding and philanthropic agencies, civil society, professional societies, and other nongovernmental organizations that provide social, financial, and technical support to reproductive health programmes. The guideline can also be used as an advocacy tool for evidence-based fertility care for everyone. The recommendations in the guideline have been developed for a global audience, while many others are mostly country-or continent-specific. Its recommendations use a population perspective that considers resource considerations, acceptability, feasibility, and impact on equity, in addition to traditional evidence analysis of balance between benefits and harms. It builds upon older manuals for the examination of infertile couples which were published by WHO several decades ago ( Rowe et al. , 1993 ), recognizing that diagnosis and treatment have vastly improved over the last few decades. The guideline also incorporates prevention, as well as the diagnosis and treatment of male, female, and unexplained infertility, offering a single source for recommendations and intervention recommendations for both biological sexes, while emphasising a comprehensive approach. We scoped and prioritized topics considering clinical areas where guidance was most needed, evidence was likely to be available, possibility for global reach and relevance, and the fact that resources to address recommendation questions were not infinite. This prioritization approach may raise some controversies on why we did not evaluate or recommend the most advanced diagnostic or treatment options, or why some topics were scheduled for future editions. However, the multi-country, multi-continent, and multidisciplinary GDG worked well in this respect, bringing insights regarding feasibility, impact on equity, and specific implementation considerations. Feedback from the ERG was taken seriously and each suggestion addressed on its own merit. The guideline recommendations represent consensus from experts from all over the world who worked together for many years. The recommendations were strictly based on current best evidence. High standards, sticking with the evidence, and management of conflict-of-interests, safeguard credibility of these and other WHO recommendations ( Sinclair et al. , 2013 ; World Health Organization, 2024b ). Some recommendations are similar to recommendations from other groups (such as the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE)), while others differ from these and have the potential to change existing practice. Similarities and differences aside, a WHO guideline on infertility should be seen as strengthening the field because WHO guidelines tend to have wide reach and are often acceptable in many settings ( World Health Organization, 2014 ; Saluja et al. , 2022 ). The guideline provides much-needed comments and guidance on presumptive confirmation of ovulation, clinical varicocele, use of ICSI for unexplained factors, among other clinical areas, and identifies evidence gaps related to the impact of antioxidant supplements among males, optimal numbers of IVF and IUI cycles, and key patient outcomes. Many recommendations were based on low or very low certainty evidence. Despite very comprehensive searches for evidence, we identified relatively few studies from LMICs. Additionally, there was a dearth of studies on patient values, preferences, and acceptability of different interventions. We identified a need for studies to focus on patient-relevant outcomes such as time to pregnancy and live births ( Mburu et al. , 2025b ). Data on the costs and cost-effectiveness of interventions were suboptimal for most interventions and very few studies assessed the feasibility of introducing interventions in different settings. Some studies had been retracted and were excluded from our evidence synthesis ( Mburu et al. , 2026 ). Future studies will need to address these issues to effectively inform subsequent editions of the guideline. Given that this is the first WHO guideline on the prevention, diagnosis, and treatment of infertility, it does not cover all aspects of infertility due to various constraints (e.g. resources). It is anticipated that subsequent editions of this guideline will have an expanded scope, allowing future recommendations to address topics that are not currently included. These include management of other personal risk factors (such as obesity, low body weight, excessive intake of alcohol, and other substances, including use of cannabis, vapes, and e-cigarettes or non-smoked/smokeless tobacco products, among others), sexual dysfunction as well as non-personal risk factors (e.g. environmental and workplace factors), fertility preservation in the context of gonadotoxic therapy, third-party reproduction (donor gametes, surrogacy), fertility care for individuals with pre-existing medical conditions that affect fertility (such as endometriosis and fibroids), hypothalamic amenorrhea, or those with obstructive, congenital, accessory gland, genital or hormonal abnormalities associated with male infertility, as well as psychosocial support for people with infertility. In males, future guidance will be needed for advanced sperm function testing, sperm retrieval techniques for obstructive and non-obstructive azoospermia, ART modalities, and non-invasive therapeutic approaches beyond antioxidant supplements. Management of PCOS involves a wide array of interventions ( Teede et al. , 2023 ) some of which are not scoped in the guideline, indicating future need for expanded scope. Guidance is also needed on the use of adjunct IVF ‘add-ons’, whose use is widespread ( van de Wiel et al. , 2020 ), and how to further minimize multiple pregnancies. New and experimental interventions in infertility are emerging, including use of artificial intelligence, equipment technology, medical treatments, among others. WHO will track these and other developments for potential consideration in subsequent updates of the guideline. The publication of the guideline recommendations will add confidence and strengthen arguments for policymakers to integrate fertility care in their reproductive health programs and agendas. For effective use of these recommendations, it is essential that the health systems at the country level create an enabling environment for the prevention, diagnosis, and treatment of infertility. This may include, for example, ensuring that infertility is included in relevant government departments, health and other policies (e.g. educational or social), strategic plans, services and financing, as well as ensuring that fertility care medications are included in essential medicines lists, training is provided for health care providers on infertility, health information systems are modified to incorporate data on infertility, and national clinical guidelines are developed on infertility. Ultimately, the impact of a guideline depends on the extent to which it informs the standards of clinical care, and in turn improves patient outcomes. A basic metric of tracking this impact is by monitoring how these recommendations are adapted by countries. Countries can adapt the recommendations to suit their national needs, based on local contexts, through inclusive engagement of all local partners, including national and subnational governments, civil society, patient organizations, and professional societies of various health care providers involved in fertility care. To enhance the uptake of the recommendations, this guideline will be disseminated through a broad network of partners, including ministries of health, international development agencies, academic institutions, professional societies, and non-governmental organizations, including non-state actors in official relations with WHO such as the American Society of Reproductive Medicine (ASRM), International Committee for Monitoring Assisted Reproductive Technologies (ICMART), and International Federation of Fertility Societies (IFFS), in collaboration with the European Society of Human Reproduction and Embryology (ESHRE), and the International Federation of Gynecology and Obstetrics (FIGO) among others. Translation of the guideline is essential ( World Health Organization, 2014 ), as is making it available in digital or online and other digital formats to improve usability ( Mehl et al. , 2021 ; World Health Organization, 2022 ). Monitoring and evaluation should be built into the implementation process to provide important lessons to continually improve implementation. Recommendations in the guideline complement—and should be interpreted and implemented alongside—existing WHO normative guidance related to the examination and processing of human semen ( World Health Organization, 2021b ), tobacco cessation in adults ( World Health Organization, 2024a ), and management of symptomatic sexually transmitted infections ( World Health Organization, 2021a ) and antenatal care ( World Health Organization, 2016 ). We welcome collaborations with all partners on all aspects of the recommendations contained in the guideline, as we all work together to advance universal access to fertility care for all.